Infologix issues SEC proxy statement regarding proposed recapitalization plan

InfoLogix, Inc. ("InfoLogix" or the "Company") (Nasdaq: IFLG), a leading technology provider of enterprise mobility solutions for the healthcare and commercial industries, today announced that it has filed a preliminary proxy statement with the U.S. Securities and Exchange Commission ("SEC") in connection with a special meeting of stockholders of InfoLogix to approve a proposed recapitalization plan of the Company and certain related matters.

On August 20, 2009, InfoLogix signed a non-binding term sheet with NewSpring Capital, LLC ("NewSpring") outlining the terms and conditions under which NewSpring and a syndicate of other undetermined investors would purchase up to $23 million of convertible preferred stock of InfoLogix, as well as warrants to purchase shares of common stock of the Company. The Company has not entered into any definitive agreements in connection with the proposed recapitalization plan. To the extent that it is consummated at all, the recapitalization plan as described in the preliminary proxy statement filed on August 21, 2009 is subject to change based upon negotiation of the final terms and execution of the definitive agreements.

http://www.infologix.com/default.aspx

Posted in:

Tags: ,

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Exploring the potential of personalized precision medicine for healthcare industry